Medexus Pharmaceuticals (MDP) Competitors

C$4.05 +0.06 (+1.50%)

As of 05/25/2026 03:59 PM Eastern

MDP vs. CPH, SUGR, ACB, FIRE, and EPI

Should you buy Medexus Pharmaceuticals stock or one of its competitors? MarketBeat compares Medexus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medexus Pharmaceuticals include Cipher Pharmaceuticals (CPH), SugarBud Craft Growers (SUGR), Aurora Cannabis (ACB), Supreme Cannabis (FIRE), and ESSA Pharma (EPI). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Cipher Pharmaceuticals (TSE:CPH) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

Cipher Pharmaceuticals has higher earnings, but lower revenue than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.21	C$11.41M	C$1.19	13.85
Medexus Pharmaceuticals	C$99.43M	1.32	C$3.26M	-C$0.02	N/A

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for Medexus Pharmaceuticals. Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
Medexus Pharmaceuticals	Neutral

Cipher Pharmaceuticals currently has a consensus target price of C$17.00, indicating a potential upside of 3.16%. Given Cipher Pharmaceuticals' higher possible upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.1% of Medexus Pharmaceuticals shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cipher Pharmaceuticals has a net margin of 60.82% compared to Medexus Pharmaceuticals' net margin of -0.27%. Cipher Pharmaceuticals' return on equity of 25.69% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%

Cipher Pharmaceuticals has a beta of 0.894897, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Medexus Pharmaceuticals has a beta of 0.5717, indicating that its stock price is 43% less volatile than the broader market.

Summary

Cipher Pharmaceuticals beats Medexus Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to SugarBud Craft Growers?

SugarBud Craft Growers (CVE:SUGR) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

0.4% of SugarBud Craft Growers shares are owned by institutional investors. Comparatively, 3.1% of Medexus Pharmaceuticals shares are owned by institutional investors. 30.2% of SugarBud Craft Growers shares are owned by insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, SugarBud Craft Growers' average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
SugarBud Craft Growers	Neutral
Medexus Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SugarBud Craft Growers	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

SugarBud Craft Growers has a net margin of 2.11% compared to Medexus Pharmaceuticals' net margin of -0.27%. SugarBud Craft Growers' return on equity of 10.07% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SugarBud Craft Growers	2.11%	10.07%	5.13%
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%

SugarBud Craft Growers has higher revenue and earnings than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SugarBud Craft Growers	C$662.89M	0.45	C$12.12M	C$1.40	8.86
Medexus Pharmaceuticals	C$99.43M	1.32	C$3.26M	-C$0.02	N/A

SugarBud Craft Growers has a beta of 2.768948, suggesting that its share price is 177% more volatile than the broader market. Comparatively, Medexus Pharmaceuticals has a beta of 0.5717, suggesting that its share price is 43% less volatile than the broader market.

Summary

SugarBud Craft Growers beats Medexus Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Aurora Cannabis (TSE:ACB) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Medexus Pharmaceuticals has lower revenue, but higher earnings than Aurora Cannabis. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	C$373.12M	0.77	-C$44.16M	-C$1.50	N/A
Medexus Pharmaceuticals	C$99.43M	1.32	C$3.26M	-C$0.02	N/A

In the previous week, Aurora Cannabis' average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aurora Cannabis	Neutral
Medexus Pharmaceuticals	Neutral

Aurora Cannabis has a beta of 0.415152, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Medexus Pharmaceuticals has a beta of 0.5717, suggesting that its stock price is 43% less volatile than the broader market.

Medexus Pharmaceuticals has a net margin of -0.27% compared to Aurora Cannabis' net margin of -1.69%. Medexus Pharmaceuticals' return on equity of -0.52% beat Aurora Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-1.69%	-1.15%	-1.87%
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%

4.2% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 3.1% of Medexus Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aurora Cannabis presently has a consensus price target of C$9.25, suggesting a potential upside of 89.16%. Given Aurora Cannabis' higher probable upside, equities analysts plainly believe Aurora Cannabis is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Summary

Medexus Pharmaceuticals beats Aurora Cannabis on 10 of the 15 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Supreme Cannabis?

Medexus Pharmaceuticals (TSE:MDP) and Supreme Cannabis (TSE:FIRE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

3.1% of Medexus Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Medexus Pharmaceuticals' average media sentiment score of 0.00 equaled Supreme Cannabis'average media sentiment score.

Company	Overall Sentiment
Medexus Pharmaceuticals	Neutral
Supreme Cannabis	Neutral

Given Supreme Cannabis' higher possible upside, analysts plainly believe Supreme Cannabis is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Supreme Cannabis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Supreme Cannabis has a net margin of 0.00% compared to Medexus Pharmaceuticals' net margin of -0.27%. Supreme Cannabis' return on equity of 0.00% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%
Supreme Cannabis	N/A	N/A	N/A

Medexus Pharmaceuticals has higher revenue and earnings than Supreme Cannabis. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Supreme Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$99.43M	1.32	C$3.26M	-C$0.02	N/A
Supreme Cannabis	C$53.29M	0.00	-C$23.65M	-C$0.03	N/A

Summary

Medexus Pharmaceuticals beats Supreme Cannabis on 8 of the 12 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to ESSA Pharma?

ESSA Pharma (CVE:EPI) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ESSA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

In the previous week, ESSA Pharma's average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ESSA Pharma	Neutral
Medexus Pharmaceuticals	Neutral

3.1% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ESSA Pharma has a net margin of 0.00% compared to Medexus Pharmaceuticals' net margin of -0.27%. ESSA Pharma's return on equity of 0.00% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ESSA Pharma	N/A	N/A	N/A
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%

Medexus Pharmaceuticals has higher revenue and earnings than ESSA Pharma. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ESSA Pharma	N/A	N/A	N/A	-C$0.99	N/A
Medexus Pharmaceuticals	C$99.43M	1.32	C$3.26M	-C$0.02	N/A

Summary

Medexus Pharmaceuticals beats ESSA Pharma on 7 of the 10 factors compared between the two stocks.

Get Medexus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDP vs. The Competition

Export

Metric	Medexus Pharmaceuticals	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$130.82M	C$2.25B	C$6.46B	C$12.16B
Dividend Yield	N/A	2.95%	2.76%	6.20%
P/E Ratio	-202.50	5.16	21.21	37.64
Price / Sales	1.32	1,770.59	554.38	11.68
Price / Cash	N/A	10.18	43.49	82.29
Price / Book	2.52	10.61	10.37	4.50
Net Income	C$3.26M	C$20.70B	C$3.57B	C$299.09M
7 Day Performance	6.02%	8.21%	6.40%	2.48%
1 Month Performance	2.02%	3.75%	3.53%	1.47%
1 Year Performance	37.76%	22.83%	34.04%	53.55%

Medexus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDP Medexus Pharmaceuticals	N/A	C$4.05 +1.5%	N/A	+47.3%	C$130.82M	C$99.43M	N/A	98
CPH Cipher Pharmaceuticals	0.5582 of 5 stars	C$17.47 -2.7%	C$17.00 -2.7%	+32.7%	C$441.66M	C$50.94M	16.64	5
SUGR SugarBud Craft Growers	N/A	C$12.25 +0.7%	N/A	+1.2%	C$294.85M	C$668.94M	7.29	44
ACB Aurora Cannabis	1.5872 of 5 stars	C$4.60 flat	C$9.25 +101.1%	-35.1%	C$271.98M	C$373.12M	N/A	1,073	Gap Up
FIRE Supreme Cannabis	N/A	N/A	N/A	N/A	C$259.40M	C$53.29M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:MDP) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medexus Pharmaceuticals (MDP) Competitors

MDP vs. CPH, SUGR, ACB, FIRE, and EPI

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Summary

How does Medexus Pharmaceuticals compare to SugarBud Craft Growers?

Summary

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Summary

How does Medexus Pharmaceuticals compare to Supreme Cannabis?

Summary

How does Medexus Pharmaceuticals compare to ESSA Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDP vs. The Competition

Medexus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medexus Pharmaceuticals (MDP) Competitors

MDP vs. CPH, SUGR, ACB, FIRE, and EPI

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Which has higher earnings & valuation, CPH or MDP?

Does the media refer more to CPH or MDP?

Do analysts rate CPH or MDP?

Do institutionals & insiders have more ownership in CPH or MDP?

Is CPH or MDP more profitable?

Which has more volatility and risk, CPH or MDP?

Summary

How does Medexus Pharmaceuticals compare to SugarBud Craft Growers?

Do institutionals and insiders hold more shares of SUGR or MDP?

Does the media refer more to SUGR or MDP?

Do analysts prefer SUGR or MDP?

Is SUGR or MDP more profitable?

Which has preferable valuation & earnings, SUGR or MDP?

Which has more risk & volatility, SUGR or MDP?

Summary

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Which has stronger earnings and valuation, ACB or MDP?

Does the media refer more to ACB or MDP?

Which has more volatility & risk, ACB or MDP?

Is ACB or MDP more profitable?

Do institutionals & insiders hold more shares of ACB or MDP?

Do analysts prefer ACB or MDP?

Summary

How does Medexus Pharmaceuticals compare to Supreme Cannabis?

Do insiders & institutionals believe in MDP or FIRE?

Does the media prefer MDP or FIRE?

Do analysts prefer MDP or FIRE?

Is MDP or FIRE more profitable?

Which has preferable earnings & valuation, MDP or FIRE?

Summary

How does Medexus Pharmaceuticals compare to ESSA Pharma?

Do analysts recommend EPI or MDP?

Does the media prefer EPI or MDP?

Do institutionals and insiders believe in EPI or MDP?

Is EPI or MDP more profitable?

Which has better earnings & valuation, EPI or MDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDP vs. The Competition

Medexus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools